Both have been demonstrated to improve lung function and possibly reduce asthma exacerbations, but only in patients with severe asthma with biomarker evidence of a type-2 phenotype, demonstrated by elevated serum periostin levels or elevated IL-13 levels in sputum [53, 54]. The gene discussed is IL13; the disease is asthma.